Target: KRAS G12C | Disease State: Cancer

Introduction / Brief Description

MRTX849 is a small molecule inhibitor of KRAS G12C invented by Array and Mirati Therapeutics. Mirati owns worldwide development rights to MRTX849 and is evaluating MRTX849 in a Phase 1/2 clinical trial in patients with advanced solid tumors that harbor KRAS G12C mutations.

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of our clinical trials.